ROCHESTER, Minn. — May 5, 2026 — Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, today announced its upcoming participation at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. The company will showcase its latest CAR T delivery technology platform, G-Link, through a comprehensive schedule of presentations, technical sessions, and exhibition activities.
During the 2026 ASGCT Annual Meeting — held from May 11-15 in Boston — Vyriad will showcase its G-Link platform, a modular “plug-and-play” protein adapter developed in collaboration with Menachem Rubenstein of the Weizmann Institute, that allows drug developers to cap and retarget existing lentiviral vectors for precise in vivo delivery. By leveraging G-Link, wild-type lentiviral vectors can be reprogrammed for in vivo applications without the need for intensive vector re-engineering, effectively shortening development timelines for next-generation CAR T and other cell therapies. Additionally, G-Link can be used to simplify ex vivo CAR T manufacturing and significantly improve T cell transduction efficiency without redesigning vectors.
“I believe that G-Link can address some of the most persistent challenges in in vivo delivery and we are excited to unveil it at ASGCT this year,” said Dr. Stephen Russell, CEO of Vyriad. “Our participation this year underscores our clear mission: to replace complex, weeks-long manufacturing cycles with precise, off-the-shelf immunotherapies. With G-Link, we aim to foster collaborations that will define the next generation of in vivo cell therapies.”
Vyriad’s VV169 in vivo CAR T program will progress into clinical development later this year, while the G-Link platform will advance towards clinical translation later in the future.
Schedule of Vyriad Activities
Workshop Presentation
- Workshop: Innovations in Targeting and Detargeting to Enhance Viral Gene Therapy
- Title: Targeted In Vivo LVV Delivery Using G-Link Adapter Proteins
- Presenter(s): Luke Russell
- Date/Time: May 11th at 1:05 PM
- Location: MCEC, Room 107ABC (Level 1)
Selected Oral Abstract Presentation
- Abstract 22: Reversible engagers redirect oncolytic VSV to tumor cells and unmodified lentiviral vectors to T cells, enabling efficient in vivo CAR T-cell generation
- Presenter: Menachem Rubenstein
Poster Presentations
- Abstract 1048: LV169, an intravenously delivered, CD3-targeted, transcriptionally regulated T-cell specific vector generates aBCMA-CAR-T cells in vivo and efficiently clears disseminated multiple myeloma tumors in a preclinical model
- Presenter: Karina Krotova
- Abstract 1065: Trimeric G-linked adaptors bind stably to trimeric VSV-G glycoproteins and redirect the entry of intravenously administered lentiviral vectors for in vivo CAR-T therapy
- Presenter: Tatenda Kadungure
- Abstract 3282: Optimizing lentiviral gene delivery for in vivo generation of PSMA-CAR T cells for the treatment of prostate cancer
- Presenter: Riya Narjari
Technical Talk at the Tools & Technology Forum
- Title: G-Link: In Vivo T Cell Targeting Simplified
- Presenter: Kah-Whye Peng
- Date/Time: May 12th at 4:15 – 4:30 PM
- Location: Exhibit Hall Presentation Theater
Exhibition Booth
- Visit the Vyriad team at Booth #1735 to learn more about G-Link.
More information about the conference can be found on the ASGCT Annual Meeting website.
About Vyriad
Vyriad is a clinical-stage biotechnology company developing targeted genetic medicines for cancer and other serious diseases. The company uses engineered viruses, viral vectors, and viral envelope glycoproteins to deliver therapeutic genes directly to selected cells. Vyriad’s programs include oncolytic virotherapy, in vivo gene therapy, and gene editing applications, with ongoing Phase 1–2 trials in multiple cancer indications. Vyriad is a privately held company based in Rochester, Minnesota.
For more information, visit www.vyriad.com
Media Contact
Jakub Cikowski
HDMZ
vyriad.pr@hdmz.com
Media Inquiries
For inquiries, please contact mediarelations@vyriad.com